Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis

NCT01527032 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

FED

Sponsor class

Conditions

Amyloidosis

Interventions

DRUG: melphalan, thalidomide and dexamethasone

Sponsor

FDA Office of Orphan Products Development